Risperdal "approvable" for autism
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's antipsychotic Risperdal (risperidone) is "approvable" for treatment of autism in adolescents and children. The sNDA, submitted Dec. 19, 2003, received a priority review. Risperdal could be the first product approved for autism...
You may also be interested in...
J&J Risperdal “Not Approvable” For Autism, Alzheimer’s Psychosis
Johnson & Johnson is considering how to proceed with Risperdalafter two supplemental applications for new indications for the atypical antipsychotic have been deemed "not approvable" by FDA
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.